Chemours Company (The) (CC) Given Daily News Impact Score of 0.55
News articles about Chemours Company (The) (NYSE:CC) have been trending very positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chemours Company (The) earned a daily sentiment score of 0.55 on Accern’s scale. Accern also assigned news articles about the specialty chemicals company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Jefferies Group Weighs in on Chemours Company (The)’s FY2018 Earnings (NYSE:CC) (americanbankingnews.com)
- Chemours Company (The) (CC) PT Raised to $55.00 at J P Morgan Chase & Co (americanbankingnews.com)
- Citigroup Inc. Raises Chemours Company (The) (CC) Price Target to $59.00 (americanbankingnews.com)
- The Chemours’ (CC) CEO Mark Vergnano on Q2 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Edited Transcript of CC earnings conference call or presentation 3-Aug-17 12:30pm GMT (finance.yahoo.com)
Chemours Company (NYSE:CC) traded up 4.58% during mid-day trading on Friday, hitting $49.31. The company had a trading volume of 2,218,172 shares. Chemours Company has a 1-year low of $8.62 and a 1-year high of $49.67. The company has a 50 day moving average of $41.37 and a 200 day moving average of $37.03. The firm has a market capitalization of $9.13 billion, a PE ratio of 32.25 and a beta of 3.63.
Chemours Company (The) (NYSE:CC) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 154.80%. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the firm posted $0.27 earnings per share. The company’s revenue was up 14.8% on a year-over-year basis. Analysts predict that Chemours Company will post $3.31 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 17th will be paid a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a dividend yield of 0.24%. The ex-dividend date is Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio is presently 8.11%.
CC has been the subject of a number of recent analyst reports. Citigroup Inc. upped their price target on Chemours Company (The) from $62.00 to $63.00 and gave the company a “buy” rating in a research report on Monday, April 17th. Susquehanna Bancshares Inc upped their target price on Chemours Company (The) from $45.00 to $55.00 and gave the stock a “positive” rating in a report on Monday, May 15th. ValuEngine upgraded Chemours Company (The) from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. BidaskClub downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a report on Saturday, June 17th. Finally, Zacks Investment Research upgraded Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $51.00 target price on the stock in a report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $44.50.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/04/chemours-company-the-cc-earns-coverage-optimism-score-of-0-55-updated-updated-updated.html.
In related news, insider Paul Kirsch sold 19,036 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $41.42, for a total value of $788,471.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Erich Parker sold 4,908 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.
About Chemours Company (The)
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.